Tissue Regenix Group (TRX)

Sector:

Financials

Index:

FTSE AIM All-Share

 61.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 71.50
  • 52 Week Low: 49.00
  • Currency: UK Pounds
  • Shares Issued: 70.57m
  • Volume: 17,805
  • Market Cap: £43.40m
  • RiskGrade: 22

Tissue Regenix gets tissue import licence, inks deal with Pennine

By Josh White

Date: Monday 25 Jun 2018

LONDON (ShareCast) - (Sharecast News) - Regenerative medical devices company Tissue Regenix Group has been granted a Human Tissue Authority (HTA) license to import and distribute its portfolio of human tissue derived products from the US for use in the UK market, it announced on Monday.
The AIM-traded firm said that, to drive commercial execution, it also signed a long term, non-exclusive UK distribution agreement with Pennine Healthcare.

It said the HTA license would initially be used for the import of the CellRight 'BioRinse' portfolio of osteoinductive bone products from the San Antonio, Texas manufacturing facility into the UK.

The board added that demand for osteoinductive regenerative medicine continued to increase in the UK.

In order to access that market effectively, it signed a three-year, non-exclusive distribution agreement with Pennine.

Tissue Regenix described Pennine as "one of the UK's leading" privately-owned manufacturers and distributors of medical devices.

With an established presence in the UK orthopaedic market, it said the agreement with Pennine would enable Tissue Regenix to further penetrate the UK orthopaedic spine market.

Under the terms of the agreement, Pennine would have access to the Tissue Regenix portfolio of novel bone and soft tissue products, which would complement Pennine's existing range of spinal implants.

"Receiving the HTA license is a pivotal milestone as we complete the integration of CellRight into the group," said Tissue Regenix chief executive officer Steve Couldwell.

"This allows us to import the BioRinse portfolio in to the UK and ultimately, over time, distribute throughout Europe to meet increasing demand for our novel regenerative medicines.

"The HTA license provides the flexibility to import, store and distribute our portfolio of innovative products, a key commercial growth driver for the group in the future."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

TRX Market Data

Currency UK Pounds
Share Price 61.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 71.50
52 Week Low 49.00
Volume 17,805
Shares Issued 70.57m
Market Cap £43.40m
RiskGrade 22

TRX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
41.53% below the market average41.53% below the market average41.53% below the market average41.53% below the market average41.53% below the market average
59.26% below the sector average59.26% below the sector average59.26% below the sector average59.26% below the sector average59.26% below the sector average
Price Trend
62.94% above the market average62.94% above the market average62.94% above the market average62.94% above the market average62.94% above the market average
36.21% above the sector average36.21% above the sector average36.21% above the sector average36.21% above the sector average36.21% above the sector average
Income Not Available
Growth
21.29% above the market average21.29% above the market average21.29% above the market average21.29% above the market average21.29% above the market average
19.27% above the sector average19.27% above the sector average19.27% above the sector average19.27% above the sector average19.27% above the sector average

TRX Dividends

No dividends found

Trades for 17-May-2024

Time Volume / Share Price
13:58 4,844 @ 61.80p
13:52 4,830 @ 62.00p
12:37 83 @ 61.10p
10:58 2 @ 61.10p
10:05 203 @ 61.80p

TRX Key Personnel

CEO Daniel Lee
CFO David Cocke

Top of Page